184 related articles for article (PubMed ID: 38274829)
1. An innovative gene expression modulating strategy by converting nucleic acids into HNC therapeutics using carrier-free nanoparticles.
Liu H; Huang Y; Li Z; Han S; Liu T; Zhao Q
Front Immunol; 2023; 14():1343428. PubMed ID: 38274829
[TBL] [Abstract][Full Text] [Related]
2. Upregulated expression of eIF3C is associated with malignant behavior in renal cell carcinoma.
Fan M; Wang K; Wei X; Yao H; Chen Z; He X
Int J Oncol; 2019 Dec; 55(6):1385-1395. PubMed ID: 31638200
[TBL] [Abstract][Full Text] [Related]
3. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
Roh JL; Park JY; Kim EH; Jang HJ
Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
[TBL] [Abstract][Full Text] [Related]
4. eIF3c: a potential therapeutic target for cancer.
Emmanuel R; Weinstein S; Landesman-Milo D; Peer D
Cancer Lett; 2013 Aug; 336(1):158-66. PubMed ID: 23623922
[TBL] [Abstract][Full Text] [Related]
5. Decreasing Eukaryotic Initiation Factor 3C (EIF3C) Suppresses Proliferation and Stimulates Apoptosis in Breast Cancer Cell Lines Through Mammalian Target of Rapamycin (mTOR) Pathway.
Zhao W; Li X; Wang J; Wang C; Jia Y; Yuan S; Huang Y; Shi Y; Tong Z
Med Sci Monit; 2017 Aug; 23():4182-4191. PubMed ID: 28854163
[TBL] [Abstract][Full Text] [Related]
6. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
Kim EH; Jang H; Shin D; Baek SH; Roh JL
Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
[TBL] [Abstract][Full Text] [Related]
7. Turing miRNA into infinite coordination supermolecule: a general and enabling nanoengineering strategy for resurrecting nuclear acid therapeutics.
Li L; He W; You W; Yan J; Liu W
J Nanobiotechnology; 2022 Jan; 20(1):10. PubMed ID: 34983557
[TBL] [Abstract][Full Text] [Related]
8. Effect of siRNA-mediated knockdown of eIF3c gene on survival of colon cancer cells.
Song N; Wang Y; Gu XD; Chen ZY; Shi LB
J Zhejiang Univ Sci B; 2013 Jun; 14(6):451-9. PubMed ID: 23733421
[TBL] [Abstract][Full Text] [Related]
9. The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer.
Roh JL; Kim EH; Park HB; Park JY
Cell Death Dis; 2013 Dec; 4(12):e956. PubMed ID: 24336076
[TBL] [Abstract][Full Text] [Related]
10. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer.
Roh JL; Kim EH; Park JY; Kim JW; Kwon M; Lee BH
Oncotarget; 2014 Oct; 5(19):9227-38. PubMed ID: 25193861
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.
Chu PY; Hu FW; Yu CC; Tsai LL; Yu CH; Wu BC; Chen YW; Huang PI; Lo WL
Oral Oncol; 2013 Jan; 49(1):34-41. PubMed ID: 22892238
[TBL] [Abstract][Full Text] [Related]
12. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
13. Eukaryotic Initiation Factor 3C Can Affect the Proliferation and Invasion of Ovarian Cancer by Regulating the p53 Signalling Pathway.
Zhang J; Yang H; Wen F; Li Q; Luo H; Zi D
Recent Pat Anticancer Drug Discov; 2024 Apr; ():. PubMed ID: 38629365
[TBL] [Abstract][Full Text] [Related]
14. Eukaryotic translation initiation factor 3, subunit C is overexpressed and promotes cell proliferation in human glioma U-87 MG cells.
Hao J; Liang C; Jiao B
Oncol Lett; 2015 Jun; 9(6):2525-2533. PubMed ID: 26137101
[TBL] [Abstract][Full Text] [Related]
15. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
16. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
Kim EH; Jang H; Roh JL
Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
[TBL] [Abstract][Full Text] [Related]
17. EIF3C Promotes Lung Cancer Tumorigenesis by Regulating the APP/HSPA1A/LMNB1 Axis.
Ding X; Hou L; Zhang H; Chen Z; Liu Z; Gong J; Tang Z; Hu R
Dis Markers; 2022; 2022():9464094. PubMed ID: 36157221
[TBL] [Abstract][Full Text] [Related]
18. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
Roh JL; Park JY; Kim EH
Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic initiation factor 3C silencing inhibits cell proliferation and promotes apoptosis in human glioma.
Hao J; Wang Z; Wang Y; Liang Z; Zhang X; Zhao Z; Jiao B
Oncol Rep; 2015 Jun; 33(6):2954-62. PubMed ID: 25823503
[TBL] [Abstract][Full Text] [Related]
20. Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer.
Shintani T; Higashisaka K; Maeda M; Hamada M; Tsuji R; Kurihara K; Kashiwagi Y; Sato A; Obana M; Yamamoto A; Kawasaki K; Lin Y; Kijima T; Kinehara Y; Miwa Y; Maeda S; Morii E; Kumanogoh A; Tsutsumi Y; Nagatomo I; Fujio Y
Oncotarget; 2018 Dec; 9(101):37520-37533. PubMed ID: 30680067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
